BioNTech SE - American Depositary Shares (BNTX)
BNTX moved a median of +0.01% 30 minutes after news, and +0.04% by the close. How BNTX actually reacts to news — the realized, point-in-time move the market made, measured across 928 labeled events over the last three years with zero look-ahead.
BNTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 925 |
| 30-min | +0.01% | 51% | 925 |
| 60-min | -0.19% | 43% | 925 |
| to close | +0.04% | 51% | 924 |
| Middle 50% of BNTX reactions | -0.60% to +0.56% |
|---|---|
| Median reaction (30-min) | +0.01% |
| Measured reactions | 928 |
Half of all BioNTech SE - American Depositary Shares news events land between -0.60% and +0.56% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BNTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 29 | +0.34% | 66% | -0.22% |
| Analyst downgrades | 11 | -0.41% | 0% | -1.20% |
| Coverage initiations | 25 | +0.19% | 56% | -0.31% |
| Rating reiterations | 128 | -0.22% | 41% | -0.14% |
| Price-target raises | 20 | -0.20% | 40% | -0.18% |
| Price-target cuts | 32 | +0.07% | 56% | +0.13% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how BNTX ranks against every other measured name →
That’s how BNTX usually reacts — get an email when it moves on news →Email me when BNTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BNTX's baseline. Nothing else.
Recent BNTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K BioNTech SE For: Oct 13 | SEC filing · Form 6-K | SEC EDGAR | +0.56% | -0.39% | |
| Form 6-K BioNTech SE For: Sep 18 | SEC filing · Form 6-K | SEC EDGAR | +0.56% | +1.02% | |
| BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients | Press release | GlobeNewswire | -1.99% | -3.09% | |
| Form 6-K BioNTech SE For: Sep 14 | SEC filing · Form 6-K | SEC EDGAR | -1.99% | -3.09% | |
| Form 6-K BioNTech SE For: Aug 28 | SEC filing · Form 6-K | SEC EDGAR | -1.35% | -0.26% | |
| Form 6-K BioNTech SE For: Aug 27 | SEC filing · Form 6-K | SEC EDGAR | -1.35% | -0.26% | |
| Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine | Press release | GlobeNewswire | -1.35% | -0.26% | |
| BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 | Press release | GlobeNewswire | -0.24% | +1.65% | |
| Form 6-K BioNTech SE For: Aug 20 | SEC filing · Form 6-K | SEC EDGAR | -0.24% | +1.65% | |
| BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update | Press release | GlobeNewswire | +1.44% | +2.66% | |
| Form 6-K BioNTech SE For: Aug 04 | SEC filing · Form 6-K | SEC EDGAR | +1.44% | +2.66% | |
| Form 6-K BioNTech SE For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +1.44% | +2.66% | |
| Form 6-K BioNTech SE For: Aug 03 | SEC filing · Form 6-K | SEC EDGAR | -1.61% | +1.36% | |
| Form 20-F/A BioNTech SE For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -0.27% | -2.64% | |
| Form 6-K BioNTech SE For: Jul 29 | SEC filing · Form 6-K | SEC EDGAR | +0.57% | +0.79% | |
| BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026 | Press release | GlobeNewswire | +0.14% | +0.04% | |
| Form 6-K BioNTech SE For: Jun 08 | SEC filing · Form 6-K | SEC EDGAR | -0.90% | -2.56% | |
| Form 6-K BioNTech SE For: Jun 01 | SEC filing · Form 6-K | SEC EDGAR | -1.58% | -5.46% | |
| BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | -0.38% | -0.43% | |
| Form 6-K BioNTech SE For: May 22 | SEC filing · Form 6-K | SEC EDGAR | -0.38% | -0.43% | |
| BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 | Press release | GlobeNewswire | -1.04% | -0.19% | |
| Form 6-K BioNTech SE For: May 15 | SEC filing · Form 6-K | SEC EDGAR | -1.04% | -0.19% | |
| Form 6-K BioNTech SE For: May 07 | SEC filing · Form 6-K | SEC EDGAR | +1.22% | -3.10% | |
| Form 6-K BioNTech SE For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +2.06% | -0.28% | |
| Form 6-K BioNTech SE For: May 05 | SEC filing · Form 6-K | SEC EDGAR | +2.06% | -0.28% | |
| Form 6-K BioNTech SE For: Apr 13 | SEC filing · Form 6-K | SEC EDGAR | +0.51% | +0.99% | |
| BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer | Press release | GlobeNewswire | +0.51% | +0.99% | |
| Form 6-K BioNTech SE For: Apr 02 | SEC filing · Form 6-K | SEC EDGAR | +0.41% | +0.81% | |
| Form 20-F/A BioNTech SE For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -0.25% | +4.00% | |
| BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer | Press release | GlobeNewswire | +0.38% | -0.38% | |
| Form 6-K BioNTech SE For: Mar 24 | SEC filing · Form 6-K | SEC EDGAR | +0.77% | +0.88% | |
| BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update | Press release | GlobeNewswire | -0.81% | +1.30% | |
| Form 20-F BioNTech SE For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -0.81% | +1.30% | |
| Form 6-K BioNTech SE For: Mar 10 | SEC filing · Form 6-K | SEC EDGAR | -0.81% | +1.30% | |
| Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 | Press release | PR Newswire | +0.23% | -0.95% | |
| BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer | Press release | GlobeNewswire | -0.33% | -1.08% | |
| Form 6-K BioNTech SE For: Jan 28 | SEC filing · Form 6-K | SEC EDGAR | -0.33% | -1.08% | |
| Form 6-K BioNTech SE For: Jan 13 | SEC filing · Form 6-K | SEC EDGAR | -0.59% | -0.14% | |
| BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -1.11% | +1.00% | |
| Form 6-K BioNTech SE For: Jan 12 | SEC filing · Form 6-K | SEC EDGAR | -1.11% | +1.00% | |
| Form 6-K BioNTech SE For: Jan 06 | SEC filing · Form 6-K | SEC EDGAR | +1.02% | +0.76% | |
| BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field | Press release | GlobeNewswire | +0.36% | -0.14% | |
| Form 6-K BioNTech SE For: Dec 18 | SEC filing · Form 6-K | SEC EDGAR | +0.27% | +0.77% | |
| Form 6-K BioNTech SE For: Dec 09 | SEC filing · Form 6-K | SEC EDGAR | -0.09% | -1.88% | |
| Form 6-K BioNTech SE For: Dec 06 | SEC filing · Form 6-K | SEC EDGAR | -0.22% | -1.74% | |
| BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer | Press release | GlobeNewswire | -0.22% | -1.74% | |
| BioNTech Achieves Minimum Condition in CureVac Exchange Offer | Press release | GlobeNewswire | +0.68% | +0.18% | |
| Form 6-K BioNTech SE For: Dec 03 | SEC filing · Form 6-K | SEC EDGAR | +0.43% | -1.11% | |
| Form 6-K BioNTech SE For: Nov 26 | SEC filing · Form 6-K | SEC EDGAR | -0.02% | +0.83% | |
| Form 6-K BioNTech SE For: Nov 12 | SEC filing · Form 6-K | SEC EDGAR | -0.15% | +2.53% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BNTX section they belong to.
Where else BNTX is measured.
BNTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BioNTech SE - American Depositary Shares's median reaction calculated?
Every labeled BNTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 928 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of BNTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BNTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.